transcription activator like effector nucleases talen and clustered regularly interspaced short palindromic repeat cas9 crispr cas9 targeting hpv16 and hpv18 e6 e7 genes clinical trial intelligence

A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ

This clinical trial, sponsored by the First Affiliated Hospital of Sun Yat-Sen University, aims to evaluate the safety and efficacy of TALEN and CRISPR/Cas9 gene editing technologies in treating HPV-related cervical intraepithelial neoplasia (CIN). Given the prevalence of HPV infections and the associated risk of cervical cancer, successful outcomes could position these gene-editing therapies as innovative treatment options in a market with significant unmet needs. The competitive landscape includes traditional HPV treatments and emerging gene therapies, necessitating thorough diligence on regulatory pathways and potential market entry strategies.

Matched by target_normalized: Transcription Activator-like Effector Nucleases (TALEN) and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 (CRISPR/Cas9) targeting HPV16 and HPV18 E6/E7 genes.